Escitalopram and sertraline seem the best choices in starting treatment for major depression, according to a meta-analysis published online in Lancet.
Researchers analyzed 117 randomized trials — comprising some 26,000 patients — of 12 new-generation antidepressants. The drugs were evaluated for efficacy and patient acceptability at the 8-week mark.
Among the conclusions:
Escitalopram, mirtazapine, sertraline, and venlafaxine were the most efficacious.
Escitalopram and sertraline showed the "best possible balance between efficacy and acceptability."
Given cost considerations, sertraline seemed the better of the two.
An editorialist, noting that the study protocol and data set are free online, writes: "A new gold standard of reliable information has been compiled for patients to review
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment